Ann Lab Med.  2015 Jan;35(1):94-98. 10.3343/alm.2015.35.1.94.

Antimicrobial Susceptibility of Clinical Isolates of Bacteroides fragilis Group Organisms Recovered from 2009 to 2012 in a Korean Hospital

Affiliations
  • 1Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea. leekcp@yuhs.ac
  • 2Department of Laboratory Medicine, Hanyang University College of Medicine, Seoul, Korea.

Abstract

BACKGROUND
Periodic monitoring of antimicrobial resistance trends of clinically important anaerobic bacteria such as Bacteroides fragilis group organisms is required. We determined the antimicrobial susceptibilities of clinical isolates of B. fragilis group organisms recovered from 2009 to 2012 in a tertiary-care hospital in Korea.
METHODS
A total of 180 nonduplicate clinical isolates of B. fragilis group organisms were collected in a tertiary care hospital. The species were identified by conventional methods: the ATB 32A rapid identification system (bioMerieux, France) and the Vitek MS matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (bioMerieux). Antimicrobial susceptibility was determined by the CLSI agar dilution method.
RESULTS
Imipenem and meropenem resistance rates were 0-6% for B. fragilis group isolates. The rate of resistance to piperacillin-tazobactam was 2% for B. fragilis and 0% for other Bacteroides species, but 17% for B. thetaiotaomicron isolates. High resistance rates to piperacillin (72% and 69%), cefotetan (89% and 58%), and clindamycin (83% and 69%) were observed for B. thetaiotaomicron and other Bacteroides spp. The moxifloxacin resistance rate was 27% for other Bacteroides spp. The MIC50 and MIC90 of tigecycline were 2-4 microg/mL and 8-16 microg/mL, respectively. No isolates were resistant to chloramphenicol or metronidazole.
CONCLUSIONS
Imipenem, meropenem, chloramphenicol, and metronidazole remain active against B. fragilis group isolates. Moxifloxacin and tigecycline resistance rates are 2-27% and 8-15% for B. fragilis group isolates, respectively.

Keyword

Bacteroides fragilis group; Antimicrobial resistance; Tigecycline; Moxifloxacin

MeSH Terms

Anti-Infective Agents/*pharmacology
Bacteroides Infections/*microbiology/pathology
Bacteroides fragilis/*drug effects/isolation & purification
Drug Resistance, Multiple, Bacterial
Humans
Imipenem/pharmacology
Inhibitory Concentration 50
Microbial Sensitivity Tests
Penicillanic Acid/analogs & derivatives/pharmacology
Piperacillin/pharmacology
Republic of Korea
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Tertiary Care Centers
Thienamycins/pharmacology
Anti-Infective Agents
Thienamycins
Imipenem
Penicillanic Acid
Piperacillin
Full Text Links
  • ALM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error